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The R620W Polymorphism of the Protein Tyrosine
Phosphatase PTPN22 Is Not Associated with Multiple
Sclerosis
To the Editor:
We recently reported the association of the minor allele
of a missense SNP (1858CrT [dbSNP accession number
rs2476601]) in the gene for hematopoietic-specific in-
tracellular protein tyrosine phosphatase (PTPN22) with
susceptibility to both rheumatoid arthritis (RA [MIM
180300]) (Begovich et al. 2004) and systemic lupus
erythematosus (SLE [MIM 152700]) (Kyogoku et al.
2004). Independently, Bottini et al. (2004) reported that
the same risk allele is also strongly associated with type
1 diabetes mellitus (T1D [MIM 222100]). This SNP re-
sults in the substitution of a highly conserved arginine
with tryptophan (R620W) in the proximal proline-rich
SH3-binding domain of PTPN22, which is important
for interaction with the c-Src tyrosine kinase, Csk (Clou-
tier and Veillette 1996; Gregorieff et al. 1998), and for
down modulation of T cell receptor signaling via phos-
phorylation of regulatory tyrosines of another Src family
kinase, Lck (Cloutier and Veillette 1999; Gjorloff-Win-
gren et al. 1999). In vitro experiments show that the
W620 variant of PTPN22 binds less efficiently to Csk
(Begovich et al. 2004; Bottini et al. 2004), suggesting
that T cells expressing this allele may be hyperrespon-
sive. Correspondingly, knockout mice deficient in the
murine orthologue of PTPN22, PEP, show selective dis-
regulation of the effector/memory T cell compartment,
with enhanced activation of Lck, hyperproliferation, and
exaggerated early signaling responses in restimulated T
cells (Hasegawa et al. 2004). These mice also sponta-
neously develop germinal centers and increased serum
levels of certain immunoglobulin isotypes; however, they
do not display overt signs of autoimmunity.
Together, these genetic and functional data suggest
that the W620 variant of this phosphatase is a signifi-
cant genetic risk factor for both organ-specific (T1D)
and systemic (RA and SLE) autoimmune syndromes,
perhaps because of enhanced activation of memory/ef-
fector T cells. These findings support the hypothesis that
there are common genetic variants contributing to gen-
eral immune dysregulation and susceptibility to auto-
immunity (Marrack et al. 2001; Wandstrat and Wake-
land 2001) and suggest that this SNP should be studied
in other autoimmune disorders.
Multiple sclerosis (MS [MIM 126200]) is a severe au-
toimmune disorder of the CNS characterized by chronic
inflammation, myelin loss, gliosis, varying degrees of ax-
onal pathology, and progressive neurological dysfunc-
tion (Hauser and Goodin 2001). A large body of re-
search supports a multifactorial etiology for MS, with
an underlying complex genetic component likely act-
ing in concert with undefined environmental exposures.
HLA-DR, within the MHC on chromosome 6p21, is the
only locus that has consistently demonstrated linkage in
studies of families with MS (Haines et al. 1996; Sawcer
et al. 1996; Barcellos et al. 2002), and both family-based
and case-control MS studies have convincingly shown a
specific association between the HLA-DR2 (DRB1*
1501, DQB1*0602) haplotype and disease susceptibility
(Fogdell-Hahn et al. 2000; Rubio et al. 2002; Barcellos
et al. 2003). HLA has been estimated to account for
17%–62% of the genetic etiology as calculated from
sibling relative risk (Haines et al. 1998); hence, much of
the genetic effect in MS remains to be explained.
To determine whether the R620W SNP in PTPN22
also plays a role in susceptibility to MS, we genotyped
two large, well-characterized, family-based data sets of
748 MS-prone families (563 single-case and 185 mul-
ticase families) comprising 3,251 individuals, including
1,086 affected individuals and 2,165 unaffected family
members. All individuals and their known ancestors
were non-Hispanic whites of European descent. Diag-
nostic criteria, ascertainment protocols, and clinical and
demographic characteristics are summarized elsewhere
(Barcellos et al. 2002, 2003). A third African Ameri-
can data set was ascertained using identical clinical cri-
teria and consisted of 398 cases and 209 controls (pri-
marily spouses of patients) (Oksenberg et al. 2004). The
appropriate institutional review boards approved all
studies, and written informed consent was obtained
from all participants. Genotyping was performed using
a Taqman Assay By Design (Applied Biosystems). Primer
and probe sequences were as follows: forward primer,
5′-CAACTGCTCCAAGGATAGATGATGA-3′; reverse
primer, 5′-CCAGCTTCCTCAACCACAATAAATG-3′;
probe for C allele, 5′-FAM-TCAGGTGTCCGTACAG-
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Table 1
P Values from PDT Analysis of White Families
with MS
Families n P
All 748 .69
Single-case 563 .48
Multicase 185 .28
With disease phenotypea:
RR course at onset 652 .59
Progressive course at onset 36 .69
With HLA-DR2 statusb:
DR2 positive 324 .91
DR2 negative 231 .22
a For multicase families, only those families in
which all members were concordant for either phe-
notype (RR course at onset or progressive course
at onset) were used for analysis; phenotypically dis-
cordant families were not used.
b HLA data were available for 555 families.
Multicase families in which all affected members
were not concordant for DR2-positive or DR2-
negative classifications were not used in the sub-
group analyses.
G-3′; and probe for T allele, 5′-VIC-TCAGGTGTCCAT-
ACAGG-3′. This assay was validated using samples of
known genotype. All family genotypes were examined
for Mendelian inconsistencies by use of PEDCHECK
(O’Connell and Weeks 1998), and any discrepancies
were addressed. Family-based association analysis was
performed using the pedigree disequilibrium test (PDT),
version 4.0 (Martin et al. 2000). P values for x2 or
Fisher’s exact tests of allele or genotype case-control
comparisons were derived using SAS, version 9.0 (SAS
Institute). No deviations from Hardy-Weinberg equilib-
rium were observed for PTPN22 R620W genotypes in
any of the patient groups, controls, or unrelated family
founders.
We performed an extensive evaluation of this poly-
morphism, using large family-based and case-control
comparisons. First, we compared the W620 allele fre-
quencies of the white probands with MS from each of
the two family-based studies with the results generated
from 1,961 white controls (Begovich et al. 2004). The
frequency of the T allele in controls was 8.7%, compared
with 9.8% in the simplex probands ( ), 8% inP p .22
the multiplex probands ( ), and 9.4% in the com-P p .65
bined patient group ( ). The frequency of thisP p .40
SNP allele in 398 African American patients with MS
was 2.9%, compared with 1.4% in 209 spousal controls
( ) and 2.4% in 409 randomly chosen AfricanP p .11
American controls ( ) (Begovich et al. 2004).P p .58
Results from PDT analyses for both the single-case
and multicase families are shown in table 1. There was
no evidence of transmission distortion in either data set
considered individually ( and .28, respectively)P p .48
or when combined for analysis ( ). Similar resultsP p .69
were also observed for PDT analyses of PTPN22 ge-
notypes in families ( ; data not shown) (MartinP p .56
et al. 2003). Families were stratified by the presence or
absence of HLA-DR2 in affected individuals, to identify
potential genetic interactions with the PTPN22 R620W
SNP. No difference in transmission of either allele was
observed in either DR2-positive or DR2-negative fam-
ilies ( and .22, respectively). To identify a genet-P p .91
ic relationship between PTPN22 R620W and clinical
presentation of MS, families were also categorized by
whether cases had an initial relapsing-remitting (RR)
course or had a primary progressive or progressive re-
lapsing (PP or PR) course. Significant results for PTPN22
R620W were not observed in either clinical subset
( in one and .69 in the other). Furthermore, noP p .59
evidence of association was present in the African Amer-
ican data set when cases were stratified by disease course
(RR at onset vs. PP or PR at onset) and then compared
( ; data not shown). Overall, we observed noP p .18
evidence of genetic association between the PTPN22
R620W polymorphism and MS susceptibility or disease
course in both the white and African American data sets.
We calculated power for PDT analyses in the families
with MS under a multiplicative model (Risch and Mer-
ikangas 1996), assuming an allele frequency of 9.0%
(derived from white controls used in this study) and a
type 1 error rate of 5%. On the basis of these assump-
tions, we estimate that we have close to 90% power to
detect a very modest genotype relative risk of 1.5 for
disease susceptibility in the family data set. This estimate
is very conservative, in that a combined total of 475
independent trios and 375 independent discordant sib
pairs (DSPs) were used for calculation of power. A total
of 582 trios and 1,467 DSPs were actually available for
the analyses, and, although this larger number of trios
and DSPs were not derived from independent families,
their inclusion is expected to increase statistical power
substantially (Martin et al. 2000). It is important to note
that, owing to the significantly lower PTPN22 SNP allele
frequency in the African American controls, compared
with that in white controls (1.4%–2.4% vs. 8.7%), there
is less power to detect modest genetic effects in the Af-
rican American case-control analysis. Under the as-
sumption of a type 1 error rate of 5%, there is 80%
power to detect a relative risk of ∼3.0–4.0. To rule out
a smaller genetic contribution to disease susceptibility
for PTPN22 R620W in this population, a larger data
set is needed.
The observation that MS is not associated with an
increased frequency of the PTPN22 W620 variant,
whereas RA, T1D, and SLE are, suggests that the latter
three diseases share a common underlying mechanism
that may not be integral to MS pathogenesis. All three
diseases associated with the PTPN22 W620 variant are
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characterized by the presence of autoantibodies (anti-
citrulline antibodies and rheumatoid factor in RA, anti-
GAD (anti–glutamate decarboxylase) antibodies in T1D,
and an array of autoantibodies in SLE) that, more often
than not, predate clinical disease. This has led to the
proposal that the PTPN22 W620 variant may predis-
pose individuals to autoimmunity by facilitating the
generation of certain disease-associated autoantibodies,
thereby contributing to disease onset and progression
(Kyogoku et al. 2004). This hypothesis is supported by
the observation that the W620 variant is strongly as-
sociated with rheumatoid factor–positive RA, whereas
there is no significant association with rheumatoid fac-
tor–negative RA (Begovich et al. 2004; Lee et al., in
press).
Interestingly, MS is thought to be primarily a T cell–
mediated disease, and, although there are reports of anti-
myelin antibodies in the sera and cerebrospinal fluid
(CSF) of patients with MS, these antibodies appear to
be of low affinity, and their role in disease pathogenesis
and progression is not well understood. Genain et al.
(1999) have observed myelin-specific infiltrating B cells
in the brains of patients with MS, and the CSF and brain
of an affected individual can show an elevated frequency
of clonally expanded B cells with properties of postger-
minal center memory or antibody-forming lymphocytes
(Baranzini et al. 1999). This apparent dichotomy can be
explained by the observation that MS has distinctive
patterns of presentation; this heterogeneity is also re-
flected in the neuropathology of MS. Recent work has
demonstrated the existence of multiple histologic phe-
notypes in which the core components of the lesion (in-
flammation, demyelination, and oligodendrocyte pa-
thology) are present in different degrees (Lucchinetti et
al. 2000). For example, some hyperacute forms are
characterized by substantial CNS inflammation, which
suggests cellular mechanisms of disease, whereas im-
munoglobulin deposition is prominent in other de-
myelinating forms. The well-documented effect of lo-
cus heterogeneity in MS raises the question of whether
distinct phenotypes are associated with distinct under-
lying genotypes. Hence, although the experimental
tools to accurately assess humoral endophenotypes in
MS are not yet available, the possibility of PTPN22
variation being a susceptibility factor in a subset of pa-
tients with a dominant antibody component warrants
further investigation.
In summary, the W620 variant of PTPN22 does not
appear to play a major role in MS pathogenesis in our
data sets. Analyses of the role of this SNP in additional
autoimmune disorders should provide hints about the
underlying mechanisms of these complex diseases as well
as a framework to begin to understand how they are
related and why certain autoimmune diseases can co-
segregate in the same families.
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Corrections to the Parameterization of Constraints
on Allele Sharing in Sibling Pairs Alter Covariate-
Parameter Estimates but Not Sharing-Probability
Estimates or Power of Tests for Linkage
To the Editor:
Errors in appendix B of our 1999 article in the Journal
(Greenwood and Bull 1999) were recently pointed out
to us (D. Weeks and H.-J. Tsai, personal communica-
tion). The simultaneous-boundary–constrained esti-
mates for presented in 1999 do not give the correctz (x )0 i
values for the covariate parameters under the null hy-
pothesis. The correct expression for the expected pro-
portion of sibling pairs sharing zero alleles identical by
